AC Immune Ltd (ACIU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AC Immune Ltd (ACIU) has a cash flow conversion efficiency ratio of -0.366x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.45 Million) by net assets ($44.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AC Immune Ltd net asset quality index to measure how much of total assets are equity-financed.
AC Immune Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how AC Immune Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AC Immune Ltd (ACIU) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
AC Immune Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC Immune Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kpx Holdings
KO:092230
|
0.002x |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
-0.105x |
|
Crexendo Inc
NASDAQ:CXDO
|
0.028x |
|
Sociedad Comercial del Plata S.A.
BA:COME
|
0.036x |
|
Evgo Inc
NASDAQ:EVGO
|
-0.100x |
|
Electromed Inc
NYSE MKT:ELMD
|
0.067x |
|
Motorcar Parts of America Inc
NASDAQ:MPAA
|
-0.032x |
|
GE Power India Limited
NSE:GEPIL
|
1.009x |
Annual Cash Flow Conversion Efficiency for AC Immune Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of AC Immune Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see AC Immune Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.93 Million | $-66.15 Million | -1.472x | -351.01% |
| 2024-12-31 | $112.27 Million | $65.84 Million | 0.586x | +255.96% |
| 2023-12-31 | $160.64 Million | $-60.41 Million | -0.376x | +13.62% |
| 2022-12-31 | $168.99 Million | $-73.57 Million | -0.435x | -53.74% |
| 2021-12-31 | $231.98 Million | $-65.69 Million | -0.283x | -2.52% |
| 2020-12-31 | $215.48 Million | $-59.52 Million | -0.276x | -236.27% |
| 2019-12-31 | $272.44 Million | $55.22 Million | 0.203x | +181.68% |
| 2018-12-31 | $177.62 Million | $-44.08 Million | -0.248x | -31.23% |
| 2017-12-31 | $116.84 Million | $-22.09 Million | -0.189x | -376.86% |
| 2016-12-31 | $142.38 Million | $-5.65 Million | -0.040x | -106.39% |
| 2015-12-31 | $71.04 Million | $44.08 Million | 0.621x | +182.63% |
| 2014-12-31 | $23.47 Million | $-17.62 Million | -0.751x | +81.57% |
| 2013-12-31 | $4.86 Million | $-19.80 Million | -4.075x | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more